For the nine months ended September 30, 1998, CVDI reported a net loss of $2,469,000, or a loss of $0.
An important highlight of the quarter was the August 28th signing of a global distribution agreement for certain CVDI diagnostic coagulation tests with Chiron Diagnostics ("Chiron"), which is in the process of being sold to the Bayer Group.
In addition to the Chiron announcement, CVDI continued to pursue its strategy of developing rapid diagnostic specialty tests for new therapeutics.
In addition, Chiron's considerable presence in the specialized areas of the hospital will facilitate the placement of TAS analyzers and provide a foundation upon which to expand distribution of future CVDI theranostic tests.
We are very excited about our new partnership with CVDI.